ATC Group: J05AX25 Baloxavir marboxil

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J05AX25 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J05 Antivirals for systemic use
3 J05A Direct acting antivirals
4 J05AX Other antivirals
5 J05AX25

Active ingredients in J05AX25

Active Ingredient

Baloxavir marboxil is a prodrug that is converted by hydrolysis to baloxavir, the active form that exerts anti-influenza activity. Baloxavir acts on the cap-dependent endonuclease (CEN), an influenza virus-specific enzyme in the polymerase acidic (PA) subunit of the viral RNA polymerase complex and thereby inhibits the transcription of influenza virus genomes resulting in inhibition of influenza virus replication.

Related product monographs

Document Type Information Source  
 XOFLUZA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 XOFLUZA Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)

United States medicines

Medicines classified under this ATC code globally

Austria (AT)

Croatia (HR)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Italy (IT)

Japan (JP)

Lithuania (LT)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.